Biocryst Pharmaceuticals, Inc. (BCRX.W)
7.24USD
4 Feb 2010
$-0.21 (-3.11%)
$7.24
--
$6.81
$6.52
595,841
788,033
$13.47
$1.15
BCRX.W
About
Overall
| Beta: | 2.80 |
| Market Cap (Mil.): | $254.29 |
| Shares Outstanding (Mil.): | 38.82 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| BCRX.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.50 | 3.76 |
| EPS (TTM): | 50.56 | -- | -- |
| ROI: | -29.74 | 1.25 | 2.30 |
| ROE: | -63.30 | 2.09 | 2.82 |
UPDATE 1-BioCryst Q4 results top Street on flu drug sales
Feb 4 (Reuters) - BioCryst Pharmaceuticals Inc reported fourth-quarter results that topped market expectations, driven by an increase in sales of its key influenza drug, sending its shares up as much as 10 percent in pre-market trade.
Shionogi says Japan OKs influenza drug peramivir
TOKYO, Jan 13 (Reuters) - Japanese drugmaker Shionogi & Co said on Wednesday it has received regulatory approval to make and sell its intravenous influenza drug, Rapiacta, in Japan.
BioCryst inks deal with 2 cos to market influenza drug
* Names Merck Serono, Hikma Pharmaceuticals as new partners
New Japanese flu drug protects mice from avian flu
WASHINGTON, Dec 21 (Reuters) - An experimental influenza drug can protect mice against H5N1 avian influenza better than the preferred drug Tamiflu, researchers reported on Monday.
Swine flu kids getting faster drug treatment: U.S
WASHINGTON (Reuters) - More than 80 percent of U.S. children severely ill with H1N1 flu have been treated swiftly with antiviral drugs, a trend that could be saving lives, U.S. health officials said on Friday.
Swine flu kids getting faster drug treatment - U.S.
* Quick anti-viral treatment can greatly reduce symptoms
Health officials to review disaster plan
WASHINGTON (Reuters) - Stung by the continuing struggle to make a vaccine against the swine flu pandemic, Health and Human Services Secretary Kathleen Sebelius said on Tuesday her department would review its approach to disaster preparedness.
US health officials to review disaster plan
WASHINGTON, Dec 1 (Reuters) - Stung by the continuing struggle to make a vaccine against the swine flu pandemic, Health and Human Services Secretary Kathleen Sebelius said on Tuesday her department would review its approach to disaster preparedness.
Nikkei hits 2-week closing high on hopes for BOJ steps
TOKYO (Reuters) - Japan's Nikkei average rose more than 2 percent to a two-week closing high on Tuesday after the Bank of Japan said it would hold an extraordinary policy meeting, sparking speculation it might take steps to support the economy.
Nikkei hits 2-wk closing high on hopes for BOJ steps
* Hopes for quantitative easing, deflation steps lift stocks
Competitors
| Price | Change | |
|---|---|---|
| Eisai Co., Ltd (4523.T) | ¥3,285.00 | -15.00 |
| GlaxoSmithKline plc (GSK.L) | £-- | -- |
| Roche Holding Ltd. (ROG.VX) | CHF-- | -- |
| Gilead Sciences, Inc. (GILD.OQ) | $46.33 | +0.24 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
